O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway


Autoria(s): LIMA, Victor V.; GIACHINI, Fernanda R.; CARNEIRO, Fernando S.; CARVALHO, Maria Helena C.; FORTES, Zuleica B.; WEBB, R. Clinton; TOSTES, Rita C.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Aims Glycosylation with beta-N-acetylglucosamine (O-GlcNAcylation) is one of the most complex post-translational modifications. The cycling of O-GlcNAc is controlled by two enzymes: UDP-NAc transferase (OGT) and O-GlcNAcase (OGA). We recently reported that endothelin-1 (ET-1) augments vascular levels of O-GlcNAcylated proteins. Here we tested the hypothesis that O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Methods and results Incubation of vascular smooth muscle cells (VSMCs) with ET-1 (0.1 mu M) produces a time-dependent increase in O-GlcNAc levels. ET-1-induced O-GlcNAcylation is not observed when VSMCs are previously transfected with OGT siRNA, treated with ST045849 (OGT inhibitor) or atrasentan (ET(A) antagonist). ET-1 as well as PugNAc (OGA inhibitor) augmented contractions to phenylephrine in endothelium-denuded rat aortas, an effect that was abolished by the Rho kinase inhibitor Y-27632. Incubation of VSMCs with ET-1 increased expression of the phosphorylated forms of myosin phosphatase target subunit 1 (MYPT-1), protein kinase C-potentiated protein phosphatase 1 inhibitor protein (protein kinase C-potentiated phosphatase inhibitor-17), and myosin light chain (MLC) and RhoA expression and activity, and this effect was abolished by both OGT siRNA transfection or OGT inhibition and atrasentan. ET-1 also augmented expression of PDZ-Rho GEF (guanine nucleotide exchange factor) and p115-Rho GEF in VSMCs and this was prevented by OGT siRNA, ST045849, and atrasentan. Conclusion We suggest that ET-1 augments O-GlcNAcylation and this modification contributes to increased vascular contractile responses via activation of the RhoA/Rho-kinase pathway.

U.S. National Institutes of Health (NIH)

National Institutes of Health (NIH)[HL-74167]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Identificador

CARDIOVASCULAR RESEARCH, v.89, n.3, p.614-622, 2011

0008-6363

http://producao.usp.br/handle/BDPI/28147

10.1093/cvr/cvq338

http://dx.doi.org/10.1093/cvr/cvq338

Idioma(s)

eng

Publicador

OXFORD UNIV PRESS

Relação

Cardiovascular Research

Direitos

restrictedAccess

Copyright OXFORD UNIV PRESS

Palavras-Chave #beta-N-acetylglucosamine #Endothelin-1 #Vascular reactivity #RhoA/Rho-kinase pathway #SMOOTH-MUSCLE-CELLS #GLCNAC-MODIFIED PROTEINS #NITRIC-OXIDE SYNTHASE #RAT SKELETAL-MUSCLE #N-ACETYLGLUCOSAMINE #NUCLEOCYTOPLASMIC PROTEINS #CARDIOVASCULAR-SYSTEM #RHO-KINASE #ENDOTHELIN #HYPERTENSION #Cardiac & Cardiovascular Systems
Tipo

article

original article

publishedVersion